BOPI 07 BR/2024 REPERTOIRE NUMERIQUE 17 ________________________________________ (11) 21580 Consulter le mémoire (51) A61K 39/395 (2018.01); A61P 35/00 (2018.01); C07K 16/28 (2018.01) ; C12N 15/11 (2018.01) (21) 1202300392 - PCT/RU2022/050096 (22) 24/03/2022 (30) RU n° 2021107773 du 24/03/2021 (54) Monoclonal antibody that specifically binds to GD2. (72) AGEEV, Sergei Andreevich (RU); CHERNYKH Yulia Sergeevna (RU); KONDINSKAIA Diana Aleksandrovna (RU); SHIGINA Valeriia Evgenevna (RU); SAKHAROVA Dina Khaidarovna (RU); GREFENSHTEIN Mariia Anatolevna (RU); STOLYAROVA Alina Konstantinovna (RU); SOLOVYEV Valéry Vladimirovich (RU); IAKOVLEV Pavel Andreevich (RU) et MOROZOV Dmitry Valentinovich (RU) (73) JOINT STOCK COMPANY ‘‘BIOCAD’’, pomeshch. 89, str. 1, d. 38, ul. Svyazi, the Settlement of Strelna, Intracity Municipality the Settlement of Strelna, SAINT PETERSBURG, 198515, Russian Federation (RU) (74) Cabinet ISIS CONSEILS (SCP), Bastos, face de l'Agence Turque de Coopération et de Coordination, B.P. 15067, YAOUNDE (CM). (57) The present invention relates to the field of biotechnology and medicine, in particular to a monoclonal antibody or antigen-binding fragment thereof that specifically binds to GD2 (ganglioside GD2). The invention further relates to nucleic acids encoding said antibody, expression vectors, host cells and methods for producing same, methods for producing the antibodies according to the invention, pharmaceutical compositions comprising the antibody according to the invention, pharmaceutical compositions comprising the antibody according to the invention and other therapeutically active compounds, methods for treating diseases or disorders mediated by GD2, uses of the antibodies or pharmaceutical compositions thereof for treating diseases or disorders mediated by GD2, and uses of the antibodies and other therapeutically active compounds for treating diseases or disorders mediated by GD2. Fig. 1
RkJQdWJsaXNoZXIy MTM1NDc3MA==